Kevin Wang

Kevin Wang, PhD, serves as Professor and Vice-Chair for Research in the Department of Neurobiology at Morehouse School of Medicine (MSM), with additional affiliation to the Neuroscience Institute in Atlanta, Georgia. His work centers on translational biomarker development for neurological disorders, bridging laboratory research with clinical applications.

Dr. Wang's academic foundation includes:

• Undergraduate: BSc in Biochemistry & Biomedical Science from the University of Guelph
• Graduate: PhD in Pharmaceutical Science from the University of British Columbia
• Postgraduate: Postdoctoral Fellowship in Pathology at Wayne State University

His research spans CNS translational biomarker discovery, neurotrauma mechanisms, epilepsy pathophysiology, molecular diagnostics, and neurotherapeutic development. Clinically, he focuses on blood-based biomarkers for traumatic brain injury (TBI), stroke, and Alzheimer's Disease, with emphasis on diagnostic validation and regulatory implementation. His work directly addresses health disparities through biomarker applications in underserved populations.

Analysis of Dr. Wang's recent publications (2020-2022) reveals a cohesive focus on blood-based biomarkers for neurological conditions, particularly TBI and epilepsy. His research integrates molecular characterization of biomarker breakdown products (e.g., GFAP fragments), multi-center clinical validation studies, and strategic frameworks for regulatory approval across international jurisdictions. The work demonstrates strong translational momentum from basic science to FDA/EMA-cleared diagnostics.

Key scientific recognition:

• FDA and European Medicines Agency (EMA) regulatory clearance for UCH-L1/GFAP blood tests as the first in vitro diagnostics for mild TBI (2018/2021)

No specific details regarding student advising or grant funding were provided in the source material, though his leadership as Vice-Chair for Research implies oversight of departmental research activities.

Dr. Wang operates within MSM's Neuroscience Institute, leveraging institutional resources for biomarker research. His international collaborations, evidenced by multi-country regulatory submissions and publications with global authorship, position his work at the forefront of neurotrauma diagnostics and health equity initiatives.